نتایج جستجو برای: booster vaccination

تعداد نتایج: 64006  

2013
Gudadappa S. Kasabi Manoj V. Murhekar Vijay K. Sandhya Ramappa Raghunandan Shivani K. Kiran Gowdra H. Channabasappa Sanjay M. Mehendale

BACKGROUND Kyasanur forest disease (KFD), a tick-borne viral disease with hemorrhagic manifestations, is localised in five districts of Karnataka state, India. Annual rounds of vaccination using formalin inactivated tissue-culture vaccine have been conducted in the region since 1990. Two doses of vaccine are administered to individuals aged 7-65 years at an interval of one month followed by per...

2016
Juan Carlos Tejedor Jerzy Brzostek Ryszard Konior Detlef Grunert Devayani Kolhe Yaela Baine Marie Van Der Wielen

We evaluated antibody persistence in children up to 5 years after administration of a combined Haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C (MenC)-tetanus toxoid (TT) conjugate vaccine coadministered with a pneumococcal conjugate vaccine. This is the follow-up study of a randomized trial (ClinicalTrials.gov registration no. NCT00334334/00463437) in which healthy childr...

Journal: :Infection and immunity 1995
R E Begue G Castellares C Cabezas J L Sanchez R Meza D M Watts D N Taylor

Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subj...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2015
Maria A Riolo Pejman Rohani

Pertussis has reemerged as a major public health concern in many countries where it was once considered well controlled. Although the mechanisms responsible for continued pertussis circulation and resurgence remain elusive and contentious, many countries have nevertheless recommended booster vaccinations, the timing and number of which vary widely. Here, using a stochastic, age-stratified trans...

Journal: :Revista panamericana de salud publica = Pan American journal of public health 2002
Idis Faingezicht Maria Luisa Avila-Aguerro Yolanda Cervantes Marc Fourneau Sue Ann Costa Clemens

OBJECTIVE The DTPw-HB/Hib pentavalent combination vaccine has been developed following recommendations of the World Health Organization for the introduction of hepatitis B (HB) and Haemophilus influenzae type b (Hib) vaccines into routine childhood vaccination programs. The objectives of this study were to: 1) analyze the immunogenicity and the reactogenicity of the DTPw-HB/Hib pentavalent comb...

2013
Mari Strengell Niina Ikonen Thedi Ziegler Anu Kantele Veli‐Jukka Anttila Ilkka Julkunen

BACKGROUND Influenza A(H1N1)pdm09 virus has been circulating in human population for three epidemic seasons. During this time, monovalent pandemic and trivalent seasonal influenza vaccination against this virus have been offered to Finnish healthcare professionals. It is, however, unclear how well vaccine-induced antibodies recognize different strains of influenza A(H1N1)pdm09 circulating in th...

2010
Behrouz Yazdanpanah Mitra Safari Shahrzad Yazdanpanah

BACKGROUND AND AIMS The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after hepatitis B virus (HBV) vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old children. METHODS This clinical trial st...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005
I S Matha S R Salunke

Purified Vero cell rabies vaccine was used to treat 19 patients who experienced fox bite. Seventeen patients survived, and 2 patients died of rabies. Maximum antibody titers determined using a rapid fluorescent focus inhibition test were 25 IU, < or =90 days after the first vaccination and were 30 IU on day 1050 after booster vaccination.

2017
Jacek Wysocki Jerzy Brzostek Ryszard Konior Falko G. Panzer Nancy A. François Sudheer M. Ravula Devayani A. Kolhe Yue Song Ilse Dieussaert Lode Schuerman Dorota Borys

To investigate long-term antibody persistence following the administration of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), we present results of 2 follow-up studies assessing antibody persistence following 2 3+1 schedules up to 4 (NCT00624819 - Study A) and 5 years (NCT00891176 - Study B) post-booster vaccination. In Study A, antibody per...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید